Lastly, the set of druggable targets with compounds developed for non-CHD indications that were modeled using higher TG as a proxy for the pharmacological action on the target included PPARG, DHODH, VEGFA, TOP1, TUBB, NDUFA13, ABCA1, BLK, and F2 (Table 1). The gene discussed is BLK; the disease is coronary artery disorder.